Chen Min-Che, founder and managing director of Asclepiumm, provides insights into the main milestones reached and the new partnership opportunities considered by this exciting biotech company, whose Antibody Switch-on Cytotoxicity (ASC) technology platform could contribute to bringing onto the global market a novel class of “smart cell-penetrating proteins” in multiple and critical therapeutic areas, encompassing oncology, anti-aging therapies, and tissue-specific hormonal products.
You founded Asclepiumm Taiwan in 2011. What prompted you to set up your own biotech company?
"Since its conception, I have deeply believed that this novel EMT antagonist holds the potential to bring groundbreaking treatments to international patients"
